Creatinine (mmol/l)   Urea (mmol/l) Treatment plasma    urine    plasma urine C (2ml/kg) 0.21 ± 0.03 2.67 ± 0.62 9.27 ± 0.37 785.85 ±116.90 Lev 0.12 ± 0.02b 9.57 ± 2.29b 8.64 ± 1.28 128.96 ± 6.10b LevG 0.18 ± 0.04 8.66 ± 0.72 19.65 ± 3.71ab 125.06 ± 10.37 LevM 0.14 ± 0.03 10.39 ± 1.42 9.85 ± 1.72 47.0 ± 6.40ac LevI5 0.20 ± 0.02ab 10.99 ± 1.29 18.89 ± 1.29ab 38.37 ± 5.32ac LevI10*     -      -      -     - Values are mean ± SEM. (n=5 per group). bp<0.05 significantly different from the control and abp<0.05, acp<0.0001 significantly different from the group treated with levcromakalim. * all died C: Control (normal saline group) Lev : Potassium channel activated group LevG: Potassium channel activated group treated with glibenclamide LevM : Potassium channel activated group treated with metformin LevI5 : Potassium channel activated group treated with 5 i.u/kg insulin LevI10: Potassium channel activated group treated with 10 i.u/kg insulin

Table 1: The effects of levcromakalim on the creatinine and urea of normal Wistar rats treated with glibenclamide (5 mg/kg), metformin (350 mg/kg) and insulin (5 & 10 i.u/kg).